Profile Image

Staff Profile

Edit

Career Summary

Qualifications

  • PhD, University of Newcastle, 11/05/1991
  • Bachelor of Science (Honours), University of Newcastle, 03/05/1986

Research

Research keywords

  • Carcinogenesis
  • Microbiology
  • Oncology
  • Oncolytic Virotherapy
  • Virology

Research expertise

  • Virology and Oncolytic Virotherapy.
  • The molecular biology of picornaviruses, and the potential use of viruses as anti-cancer agents.

Fields of Research

CodeDescriptionPercentage
111200Oncology And Carcinogenesis50
110399Clinical Sciences Not Elsewhere Classified35
030499Medicinal And Biomolecular Chemistry Not Elsewhere Classified15

Memberships

NHMRC Committee

  • Group review panel member NHMRC 2001-2003

Awards

HMRI Young Medical Researcher of the Year

1998HMRI Young Medical Researcher of the Year
Hunter Medical Institute (Australia)

Invitations

3rd International Conference on Oncolytic Viruses as Cancer Therapeutics
Mayo Clinic, Canada (Conference Presentation - non published.)
2005
Edit

Highlighted Publications

For publications that are currently unpublished or in-press, details are shown in italics.

YearCitationAltmetricsLink
2005Shafren DR, Sylvester DE, Johansson ES, Campbell IG, Barry RD, 'Oncolysis of human ovarian cancers by echovirus type 1', International Journal of Cancer, 115 320-328 (2005) [C1]
2005Au GG, Lindberg AM, Barry RD, Shafren DR, 'Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21', International Journal of Oncology, 26 1471-1476 (2005) [C1]

Co-authors: GOUGH AU

2004Johansson ES, Xing L, Cheng R, Shafren DR, 'Enhanced cellular receptor usage by a bioselected variant of Coxsackievirus A21', Journal of Virology, 78, No.22 12603-12612 (2004) [C1]

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Click on a category title below to expand the list of citations for that specific category.

Journal article (22 outputs)

YearCitationAltmetricsLink
2012Skelding KA, Barry RD, Shafren DR, 'Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride', Investigational New Drugs, 30 568-581 (2012) [C1]

Co-authors: KATHRYN SKELDING

2011Wood LG, Powell H, Grissell TV, Davies BL, Shafren DR, Whitehead BF, et al., 'Persistence of rhinovirus RNA and IP-10 gene expression after acute asthma', Respirology, 16 291-299 (2011) [C1]
2011Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR, 'Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18', Virology Journal, 8 1-6 (2011) [C1]
2009Haley ES, Au GG, Carlton BR, Barry RD, Shafren DR, 'Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer', Journal of Molecular Medicine, 87 385-399 (2009) [C1]
2009Skelding KA, Barry RD, Shafren DR, 'Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21', Breast Cancer Research and Treatment, 113 21-30 (2009) [C1]
2008Powell H, Smart JM, Wood LG, Grissell TV, Shafren DR, Hensley MJ, Gibson PG, 'Validity of the common cold questionnaire (CCQ) in asthma exacerbations', PLoS ONE, 3 e1802 (2008) [C1]
2008Howland LJ, Au GG, Barry RD, Shafren DR, 'Potent oncolytic activity of human enteroviruses against human prostate cancer', Prostate, 68 577-587 (2008) [C1]
2007Au GG, Lincz L, Enno A, Shafren DR, 'Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma', British Journal of Haematology, 137 133-141 (2007) [C1]
2005Shafren DR, Sylvester DE, Johansson ES, Campbell IG, Barry RD, 'Oncolysis of human ovarian cancers by echovirus type 1', International Journal of Cancer, 115 320-328 (2005) [C1]
2005Grissell TV, Powell H, Shafren DR, Boyle MJ, Hensley MJ, Jones PD, et al., 'Interleukin-10 gene expression in acute virus-induced asthma', American Journal of Respiratory and Critical Care Medicine, 172 433-439 (2005) [C1]
2005Au GG, Lindberg AM, Barry RD, Shafren DR, 'Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21', International Journal of Oncology, 26 1471-1476 (2005) [C1]

Co-authors: GOUGH AU

2004Johansson E, Ekstrom J-O, Shafren DR, Frisk G, Hyypia T, Edman K, Lindberg A, 'Cell culture propagation and biochemical analysis of the Ljungan virus prototype strain', Biochemical and Biophysical Research Communications, 317 1023-1029 (2004) [C1]
2004Hansbro NG, Johansson ES, Au GG, Lindberg A, Barry RD, Shafren DR, 'Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection', Journal of Virology, 78 1431-1439 (2004) [C1]
2004Shafren DR, Au GG, Nguyen T, Barry RD, Hansbro NG, Harvey ES, et al., 'Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21', Clinical Cancer Research, 10 53-60 (2004) [C1]
2004Johansson ES, Xing L, Cheng R, Shafren DR, 'Enhanced cellular receptor usage by a bioselected variant of Coxsackievirus A21', Journal of Virology, 78, No.22 12603-12612 (2004) [C1]
2004Hansbro NG, Beagley LG, Christiansen D, Loveland BE, Johansson ES, Beagley KW, et al., 'Novel role for decay-accelerating factor in Coxsackievirus A21-mediated cell infectivity', Journal of Virology, 78 12677-12682 (2004) [C1]
2003Johansson SE, Niklasson B, Tesh R, Shafren DR, Travassos APA, Lindberg MA, 'Molecular characterization of M1146, an American isolate of Ljungan virus (LV) reveals the presence of a new LV genotype', Journal of General Virology, 84 837-844 (2003) [C1]
2000Thorne RF, Marshall JF, Shafren DR, Gibson PG, Hart IR, Burns GF, 'The integrins alpha 3 beta 1 and alpha 6 beta 1 physically and functionally associate with CD36 in human melanoma cells', Journal of Biological Chemistry, 275 (45) 35264-35275 (2000) [C1]
2000Shafren D, Dorahy DJ, Thorne R, Barry R, 'Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 cell infection', Journal of General Virology, 81 889-894 (2000) [C1]

Co-authors: RICK THORNE

1999Shafren DR, Gardner J, Mann V, Antalis T, Suhrbier A, 'Picornavirus receptor down-regulation by plasminogen activator inhibitor type 2', Journal of Virology, 73,No.9 7193-7198 (1999) [C1]
1998Shafren DR, Dorahy DJ, Thorne RF, Kinoshita T, Barry RD, Burns GF, 'Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity', The Journal of Immunology, 160 2318-2323 (1998) [C1]

Co-authors: RICK THORNE

1998Shafren DR, 'Viral cell entry induced by cross-linked decay-accelerating factor', Journal of Virology, 72(11) 9407-9412 (1998) [C1]
Show 19 more

Conference (12 outputs)

YearCitationAltmetricsLink
2011Shafren DR, Au GG, Davies B, Chan E, Stewart J, 'Pre-clinical oncolytic activity of coxsackievirus a21 in pancreatic cancer', Annals of Oncology, Barcelona, Spain (2011) [E3]

Co-authors: GOUGH AU

2011Yee YWV, Chan SHE, Shafren DR, Au GG, 'Oncolytic activity of coxsackievirus A21 in human lung cancer: A novel targeted anti-cancer strategy', Journal of Thoracic Oncology, Amsterdam, The Netherlands (2011) [E3]

Co-authors: GOUGH AU

2011Shafren DR, Farrelly M, Croft AJ, Davies B, Stewart J, Ingham R, et al., 'CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]

Co-authors: GOUGH AU

2010Shafren DR, Hersey P, Smithers M, 'Phase I evaluation of the intralesional administration of the oncolytic Picornavirus, Coxsackievirus A21 (CAVATAKTM) in patients with late stage melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2007Wark PA, Grissell TV, Davies B, Mimica J, Oldham R, Shafren DR, Gibson PG, 'Bronchial epithelial cell (BEC) response to clinical rhinovirus (clin-RV) isolates from ASTHMATICS compared to laboratory (lab-RV) strains', American Journal of Respiratory and Critical Care Medicine (American Thoracic Society 2007 International Conference Abstracts), San Francisco (2007) [E3]
2007Skelding KA, Johansson ES, Au GG, Barry RD, Shafren DR, 'CAVATAK TM has anti-cancer properties against human metastatic breast cancer', Fourth International Conference on Oncolytic Viruses as Cancer Therapeutics, Carefree, Arizona (2007) [E3]
2006Wark PA, Wood LG, Grissell TV, Davies B, Shafren DR, Powell HG, et al., 'Acute virus-induced asthma is characterised by increased expression of toll-like receptors (TLR)-2', Respirology, Canberra (2006) [E3]
2006Au GG, Johansson ES, Berry L, Skelding KA, Haley ES, Barry RD, Shafren DR, 'Coxsackievirus A21 as an oncolytic virotherapy agent for human cancers', Northern Lights EUROPIC 2006, Inari, Finland (2006) [E3]
2006Grissell TV, Davies B, Mimica JL, Shafren DR, Gibson PG, Wark PA, 'Bronchial epithelial cell response to clinical rhinoviruses isolated from asthmatics compared to laboratory rhinovirus strains', Respirology, Canberra (2006) [E3]
2005Shafren DR, Au GG, Berry LJ, Haley ES, Skelding KA, Barry RD, 'The human enterovirus, Coxsackievirus A21, exhibits oncolytic activity across a spectrum of cancer types', Proceedings of the 96th American Association for Cancer Research Annual Meeting, Anaheim, California (2005) [E3]
2005Berry LJ, Haley ES, Skelding KA, Au GG, Barry RD, Shafren DR, 'Oncolytic activity of enteroviruses across a spectrum of human cancer types', Third Annual Australian Virology Group Meeting, Phillip Island, VIC (2005) [E3]
2004Skelding KA, Haley ES, Shafren DR, Barry RD, 'Viral oncolysis of human breast cancer', The Hunter Medical Research Institute Inaugural Cancer Conference, - (2004) [E3]

Co-authors: KATHRYN SKELDING

Show 9 more
Edit

Grants and Funding

No funding.

Edit

Research Supervision

Number of current supervisions3
Total current UoN PhD EFTSL1

For supervisions undertaken at an institution other that the University of Newcastle, the institution name is listed below the program name.

Current Supervision

CommencedProposed
Completion
ProgramSupervisor TypeResearch Title
20142018PhD (Immunology & Microbiol)Co-SupervisorInvestigation of Oncolytic CVA21 as a Potential Treatment for Pancreatic Cancer
20112015PhD (Immunology & Microbiol)Co-SupervisorCombination of Oncolytic Coxsackievirus A21 with Conventional Chemotherapy for the Treatment of Melanoma
20112015PhD (Immunology & Microbiol)Co-SupervisorInvestigation of Oncolytic Coxsackievirus A21 as a Potential Treatment for Lung Cancer

Past Supervision

YearProgramSupervisor TypeResearch Title
2014PhD (Immunology & Microbiol)Co-SupervisorLow Pathogenic Human Enteroviruses as Novel Anti-Cancer Agents Against Malignant Glioma
2009PhD (Immunology & Microbiol)Principal SupervisorEnteroviral-Mediated Oncolysis of Cancer: Evaluation of Efficacy and Obstacles to Therapeutic Success
2009PhD (Immunology & Microbiol)Principal SupervisorEnteroviruses as Novel Oncolytic Agents for the Control of Human Prostate Cancer
2008PhD (Immunology & Microbiol)Principal SupervisorViral Oncolysis of Human Breast Cancer
2005PhD (Immunology & Microbiol)Principal SupervisorControl of Cancer Progression by Virotherapy
2003PhD (Immunology & Microbiol)Sole SupervisorMechanisms of Cell Entry and Release of Coxsackievirus B3 (CVB3)
2003PhD (Immunology & Microbiol)Principal SupervisorCellular Receptor Interactions of C Cluster Coxsackie A Viruses
Edit

Associate Professor Darren Shafren

Work Phone(02) 4913 8158
Fax(02) 4913 8814
Email
PositionAssociate Professor
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
The University of Newcastle, Australia
Focus AreaImmunology and Microbiology
Office
DMB305,
David Maddison Clinical Sciences Building,
David Maddison Clinical Sciences Building
URL:www.newcastle.edu.au/profile/darren-shafren